Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quigley Pharma has said preliminary follow up of study evaluating its cachexia drug, showed it to be effective in delaying the onset of the disease in mice.
Subscribe to our email newsletter
The study concluded that QR-443 was as effective in delaying the progression of cachexia when given orally as it had been shown to be when administered intra-peritoneally in a previous study. The new data compliments the previous study results demonstrating a correlation between effectiveness and the frequency of administration of the QR-443 compound.
Cachexia is an extremely debilitating and life threatening, wasting syndrome associated with chronic diseases such as cancer, AIDs, chronic renal failure, COPD and rheumatoid arthritis, where inflammation has a significant impact and patients experience loss of weight, muscle atrophy, fatigue, weakness and decreased appetite.
QR-443 has been shown in previous preclinical studies to inhibit the production of TNF-alpha and IFN-gamma and reduced other inflammatory cytokines associated with Cachexia.
“These findings in addition to previous work show that the compound warrants continued R&D. The company will be preparing experiments to support the significance of this data with continued research,” said Dr Richard Rosenbloom, COO of Quigley Pharma.